STOCK TITAN

Champlain reports 4.9% SI-BONE (SIBN) stake in Schedule 13G filing

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Champlain Investment Partners, LLC reported beneficial ownership of 2,108,944 shares of SI-BONE, Inc. common stock, representing 4.9% of the class as of 09/30/2025. Champlain has sole voting power over 1,337,489 shares and sole dispositive power over 2,108,944 shares, with no shared voting or dispositive power.

The firm files as an institutional investment adviser and certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose or effect of changing or influencing control of SI-BONE, Inc.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Champlain Investment Partners, LLC
Signature:Matthew Garcia
Name/Title:Chief Compliance Officer
Date:02/12/2026

FAQ

What does Champlain Investment Partners’ Schedule 13G for SIBN show?

Champlain Investment Partners’ Schedule 13G shows it beneficially owns 2,108,944 shares of SI-BONE, Inc. common stock, equal to 4.9% of the outstanding class. The filing characterizes this as ordinary-course investing, not aimed at changing or influencing control of SI-BONE.

How many SI-BONE (SIBN) shares does Champlain Investment Partners own?

Champlain Investment Partners reports beneficial ownership of 2,108,944 shares of SI-BONE common stock, representing 4.9% of the class. This ownership is below the 5% threshold often associated with larger reporting positions but still reflects a meaningful institutional stake in the company.

What voting and dispositive powers does Champlain have over SIBN shares?

Champlain has sole voting power over 1,337,489 SI-BONE shares and sole dispositive power over 2,108,944 shares, with no shared voting or dispositive authority. This means Champlain alone decides how those shares are voted and when they may be sold or otherwise disposed of.

Is Champlain Investment Partners seeking to influence control of SI-BONE (SIBN)?

Champlain certifies the SI-BONE shares were acquired and are held in the ordinary course of business, not to change or influence control. The firm also states the holdings are not related to any transaction intended to affect control, aside from limited proxy nomination activities.

Why is Champlain Investment Partners filing a Schedule 13G on SIBN?

Champlain files Schedule 13G because it is an institutional investor that crossed a reporting threshold in SI-BONE stock and qualifies for the short-form 13G. The firm reports a 4.9% passive stake and confirms its role as an investment adviser under the applicable SEC rule.

What percentage of SI-BONE (SIBN) does Champlain’s stake represent?

Champlain’s reported beneficial ownership of 2,108,944 SI-BONE shares represents 4.9% of the company’s outstanding common stock. This percentage places Champlain just under the 5% level commonly associated with larger holders, while still disclosing a notable institutional position.
Si-Bone

NASDAQ:SIBN

SIBN Rankings

SIBN Latest News

SIBN Latest SEC Filings

SIBN Stock Data

665.19M
39.46M
2.98%
96.62%
5.01%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA